NASDAQ:REPL - Replimune Group Stock Price, Forecast & News

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group Inc (NASDAQ:REPL) posted its earnings results on Thursday, February, 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.10. View Replimune Group's Earnings History.

Replimune Group is scheduled to release their next quarterly earnings announcement on Friday, June 26th 2020. View Earnings Estimates for Replimune Group.

5 Wall Street analysts have issued twelve-month price objectives for Replimune Group's stock. Their forecasts range from $12.50 to $30.00. On average, they anticipate Replimune Group's share price to reach $24.10 in the next twelve months. This suggests a possible upside of 42.7% from the stock's current price. View Analyst Price Targets for Replimune Group.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Replimune Group.

Media stories about REPL stock have been trending very negative recently, according to InfoTrie. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Replimune Group earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the immediate future. View News Stories for Replimune Group.

Replimune Group saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 578,100 shares, an increase of 6.4% from the January 15th total of 543,500 shares. Based on an average daily trading volume, of 189,200 shares, the days-to-cover ratio is presently 3.1 days. Currently, 4.7% of the shares of the company are short sold. View Replimune Group's Current Options Chain.

Some companies that are related to Replimune Group include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), Beam Therapeutics (BEAM), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS), Twist Bioscience (TWST) and Adverum Biotechnologies (ADVM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Amarin (AMRN), Fate Therapeutics (FATE), Energy Transfer LP Unit (ET), Pfizer (PFE), Axsome Therapeutics (AXSM), Cronos Group (CRON), Immunomedics (IMMU) and Carnival (CCL).

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Replimune Group's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.21%), FMR LLC (2.71%), Emerald Advisers LLC (2.48%), Emerald Mutual Fund Advisers Trust (2.46%), Victory Capital Management Inc. (1.03%) and Victory Capital Management Inc. (1.03%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, Joseph P Slattery, Philip Astley-Sparke and Robert Coffin. View Institutional Ownership Trends for Replimune Group.

REPL stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Goldman Sachs Group Inc. and New York State Common Retirement Fund. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Philip Astley-Sparke and Robert Coffin. View Insider Buying and Selling for Replimune Group.

REPL stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, FMR LLC, Marshall Wace North America L.P., Emerald Advisers LLC, Bank of Montreal Can, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC and Victory Capital Management Inc.. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes and Joseph P Slattery. View Insider Buying and Selling for Replimune Group.

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of REPL stock can currently be purchased for approximately $16.89.

Replimune Group has a market capitalization of $540.63 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe.View Additional Information About Replimune Group.

The official website for Replimune Group is http://www.replimune.com/.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-995-2443 or via email at [email protected]